HIMS & HERS Health (HIMS) Q4 income 2024
Hims & Hers Health The stocks rose by 18% on Monday by prolonged trade after investors had passed better than expected income and profits and instead concentrated on the disappointing gross strain.
The company led the analysts from LSEG compared to consensus estimates:
- Win each share: 11 cents expected compared to 10 cents
- Revenue: 481 million US dollars compared to $ 470 million expected
According to a publication, sales at Telemealth Society rose by 95%in the fourth quarter of USD 246.6 million in the same period of the previous year.
The company’s gross margin or the profit, which was left behind after taking the costs of the sold goods, was 77%, while the analysts surveyed by Street Account expected 78.4%.
It is the second major decline in stock for HIMS & Hind in a few days. The shares fell by 26%on Friday after the US Food and Drug Administration announced that the lack of Semaglutid injection products was solved.
In May, HIMS & HERS, an increased Semaglutide, began prescribing the active ingredient in Novo Nordisks Blockbuster GLP-1 medication Ozempic and Wegovy. The company was a breakout star in the digital health sector in 2024, partly due to the success of its popular new weight loss offer.
The company stated that its GLP-1 offer 2024 generated sales of more than $ 225 million. The share rose by around 200%a year.
Composite drugs are custom -made alternatives to brand medication that should meet the needs of a certain patient, and compouss can produce if brand treatments are lacking. The FDA said on Friday that it would be against Connecter for violations for the next 60 to 90 days.
Hims & Hers said about the winning call that Semaglutid is probably not offered on the platform after the first quarter.
“We have to notify customers in the coming one or two months that they have to look for alternative options for commercial doses,” said Andrew Dudum, CEO from HIMS & HERS, when calling. “I would suspect that many of these patients will try to go to the open market and to secure a brand option in any form factor.”
Some patients can still be able to access an increased Semaglutid if it is clinically necessary, the company added.
The company’s weight loss offer primarily consists of its oral drugs and the generic medication liraglutid, which it wants to introduce on its platform this year. With the exception of contributions from Compounded Semaglutide, the offer of weight loss in 2025 will achieve at least 725 million US dollars for income of at least $ 725 million.
HIMS & HERS also offers treatments for skin care, mental health, sexual health and hair care.
Turnover for non-GLP-1 products rose by 43% to $ 1.2 billion for the whole year, “what to achieve one year earlier,” said Yemi Okupe, Chief Financial Officer Yemi Okupe in a press release.
“The success we experience reflects a direct reflection of our improvement in the ability to democratize access to high -quality and personalized care in each of our specialties,” said Okupe.
The net profit rose to $ 26.01 million or 11 cents per share of USD 1.25 million or 1 cents per share in the previous year. According to StreetCcount, the company reported an adjusted profit of $ 54.1 million and met the estimates of the analysts.
In the first quarter, HIMS & HERS expects sales of $ 540 million to $ 540 million, while analysts expected $ 497 million. According to the company, the adjusted profit will be between 55 and 65 million US dollars for this period.
Hims & Hin will make his quarterly call with investors at 5:00 p.m.
– Brandon Gomez from CNBC contributed to this report.
